Page last updated: 2024-10-15

myxin

Description

myxin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135452479
CHEMBL ID4210631
SCHEMBL ID29928
MeSH IDM0046652

Synonyms (27)

Synonym
nsc-306757
3c antibiotic
myxin
13925-12-7
nsc306757
6-methoxy-1-phenazinol 5,10-dioxide
1-hydroxy-6-methoxyphenazine 5,10-dioxide
6-methoxy-5,10-dioxido-phenazine-5,10-diium-1-ol
1-phenazinol, 6-methoxy-, 5,10-dioxide
brn 0622031
nsc 306757
5-23-13-00363 (beilstein handbook reference)
qbe6kou32s ,
unii-qbe6kou32s
6-methoxy-phenazinol-5,10-dioxide
6-methoxy-1-phenazinol-5,10-dioxide
myxin [mi]
SCHEMBL29928
myxine
IMHLRMYGNZXFEO-UHFFFAOYSA-N
Q27287175
CHEMBL4210631
6-methoxy-5,10-dioxidophenazine-5,10-diium-1-ol
HY-N10139
DTXSID20865411
5-hydroxy-6-methoxy-10-oxo-10lambda~5~-phenazin-1(5h)-one
CS-0311351

Research Excerpts

Overview

Myxin is a well-known antibiotic that had been used for decades.

ExcerptReference
"Myxin is a well-known antibiotic that had been used for decades. "( Functional and Structural Analysis of Phenazine O-Methyltransferase LaPhzM from Lysobacter antibioticus OH13 and One-Pot Enzymatic Synthesis of the Antibiotic Myxin.
Du, L; Guiza Beltran, D; Jiang, J; Schacht, A; Wright, S; Zhang, L, 2018
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1364438Antiproliferative activity against human MOLM13 cells after 24 hrs under 2% O2 condition by WST-1 assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.
AID1726722Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by WST-1 assay2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID1364436Antiproliferative activity against human MOLM13 cells after 24 hrs under 19% O2 condition by WST-1 assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.
AID1726731Effective permeability of the compound in PBS at 50 uM incubated for 5 hrs by PAMPA2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID1726725Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by WST-1 assay2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID1726721Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by WST-1 assay2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]